Prometheus Biosciences Performance

RXDXDelisted Stock  USD 199.92  0.24  0.12%   
The company holds a Beta of 0.8, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Prometheus Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Prometheus Biosciences is expected to be smaller as well. Prometheus Biosciences right now holds a risk of 0.0%. Please check Prometheus Biosciences potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Prometheus Biosciences will be following its historical price patterns.

Risk-Adjusted Performance

0 of 100

 
Low
 
High
Very Weak
Over the last 90 days Prometheus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, Prometheus Biosciences is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow257.3 M
  

Prometheus Biosciences Relative Risk vs. Return Landscape

If you would invest (100.00) in Prometheus Biosciences on December 29, 2023 and sell it today you would earn a total of  100.00  from holding Prometheus Biosciences or generate -100.0% return on investment over 90 days. Prometheus Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Prometheus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  

Prometheus Biosciences Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Prometheus Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Prometheus Biosciences, and traders can use it to determine the average amount a Prometheus Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
RXDX
Based on monthly moving average Prometheus Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prometheus Biosciences by adding Prometheus Biosciences to a well-diversified portfolio.

Prometheus Biosciences Fundamentals Growth

Prometheus Stock prices reflect investors' perceptions of the future prospects and financial health of Prometheus Biosciences, and Prometheus Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prometheus Stock performance.

About Prometheus Biosciences Performance

To evaluate Prometheus Biosciences Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Prometheus Biosciences generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Prometheus Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Prometheus Biosciences market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Prometheus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases . Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.

Things to note about Prometheus Biosciences performance evaluation

Checking the ongoing alerts about Prometheus Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prometheus Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Prometheus Biosciences is not yet fully synchronised with the market data
Prometheus Biosciences has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (141.75 M) with loss before overhead, payroll, taxes, and interest of (106.04 M).
Prometheus Biosciences currently holds about 95.96 M in cash with (123.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.35.
Over 81.0% of the company shares are owned by institutional investors
Evaluating Prometheus Biosciences' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Prometheus Biosciences' stock performance include:
  • Analyzing Prometheus Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prometheus Biosciences' stock is overvalued or undervalued compared to its peers.
  • Examining Prometheus Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Prometheus Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prometheus Biosciences' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Prometheus Biosciences' stock. These opinions can provide insight into Prometheus Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Prometheus Biosciences' stock performance is not an exact science, and many factors can impact Prometheus Biosciences' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Prometheus Biosciences information on this page should be used as a complementary analysis to other Prometheus Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance